CMMB Stock — Chemomab Therapeutics Ltd.: Cash, EV, Pipeline

What they do

Chemomab is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity.

Source: 10-K FY2022 via SEC EDGAR

Share price

$1.32

Market cap

$10.6M

Cash

$6.7M

Enterprise value

$3.9M

Balance sheet

Cash	$6.7M
Debt	$0.0M
Net cash	$6.7M
Enterprise value	$3.9M
Basic shares	7.2M shares
Fully diluted shares	8.6M shares
Fully diluted market cap	$11.3M
Cash per share	$0.93
Quarterly burn	$7.5M
Cash runway	0.9 quarters

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

7.2M

Pre-funded warrants

0.8M

Options

0.4M

RSUs

0.1M

Warrants

0.1M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

8.6M

Cap table as of 2025-12-31.

Price history

Loading CMMB daily closes…

Loading price history…

Upcoming catalysts

No upcoming catalysts on file for this company.

Full readout calendar →

Pipeline assets

CM-101

Phase 2 · Active Modality: monoclonal antibody

Target CCL24

Indications

Primary sclerosing cholangitis (PSC) (Phase 2)
Systemic sclerosis (SSc) (Phase 2)
NASH / liver fibrosis (Phase 2)

Catalysts

— second half of 2024

Status note Humanized monoclonal antibody targeting CCL24. Phase 2 study in PSC ongoing; Phase 2 ABATE trial in SSc enrolling (IND cleared Feb 21, 2023); Phase 2a liver fibrosis biomarker trial in NASH completed.

Per-asset detail extracted from the 10-Q filed 2023-05-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	80,000	no change	0.01%	2026-08-14
Ikarian Capital	51,793	no change	0.01%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CMMB — Chemomab Therapeutics Ltd. ☆